2010
KDOQI US Commentary on the 2009 KDIGO Clinical Practice Guideline for the Care of Kidney Transplant Recipients
Bia M, Adey DB, Bloom RD, Chan L, Kulkarni S, Tomlanovich S. KDOQI US Commentary on the 2009 KDIGO Clinical Practice Guideline for the Care of Kidney Transplant Recipients. American Journal Of Kidney Diseases 2010, 56: 189-218. PMID: 20598411, DOI: 10.1053/j.ajkd.2010.04.010.Peer-Reviewed Original ResearchMeSH KeywordsClinical ProtocolsCreatinineGlomerular Filtration RateGlucocorticoidsHumansImmunocompromised HostImmunosuppression TherapyKidney DiseasesKidney TransplantationLife StyleLip NeoplasmsMonitoring, PhysiologicNeoplasmsPostoperative CarePractice Guidelines as TopicSkin NeoplasmsTransplantation, HomologousUnited StatesConceptsKidney transplant recipientsKidney Foundation Kidney Disease Outcomes Quality InitiativeKidney Disease Outcomes Quality InitiativeKDIGO guidelinesTransplant recipientsNational Kidney Foundation Kidney Disease Outcomes Quality InitiativeUS kidney transplant recipientsKDIGO Clinical Practice GuidelineKDOQI US CommentaryClinical practice guidelinesSpecific patient populationsKDIGO recommendationsPosttransplant periodTransplant careTransplant centersUS patientsPatient populationTransplant nephrologistsPractice guidelinesCardiovascular careTransplant guidelinesLifestyle changesComplex careExcellent road mapCare
2004
Renal transplant recipients over aged 60 have diminished immune activity and a low risk of rejection
Friedman AL, Goker O, Kalish MA, Basadonna GP, Kliger AS, Bia MJ, Lorber MI. Renal transplant recipients over aged 60 have diminished immune activity and a low risk of rejection. International Urology And Nephrology 2004, 36: 451-456. PMID: 15783123, DOI: 10.1007/s11255-004-8685-2.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAdultAge FactorsAgedChildChild, PreschoolGraft RejectionHumansImmunosuppression TherapyKidney TransplantationMiddle AgedRisk FactorsConceptsRenal transplant recipientsTransplant recipientsOlder patientsYounger patientsChronologic ageActual patient survival ratesOlder renal transplant recipientsPrimary kidney transplantsYear graft survivalPatient survival ratesOrgan Transplant CenterAcute rejectionCadaveric recipientsEquivalent immunosuppressionGraft survivalImmunosuppression strategiesImmunosuppressive protocolsConsecutive recipientsKidney transplantDonor kidneysTransplant centersGeriatric patientsYounger recipientsOutcome analysisStudy group
2002
Treatment of Osteoporosis and Osteopenia in Long‐term Renal Transplant Patients with Alendronate
Cruz DN, Brickel HM, Wysolmerski JJ, Gundberg CG, Simpson CA, Kliger AS, Lorber MI, Basadonna GP, Friedman AL, Insogna KL, Bia MJ. Treatment of Osteoporosis and Osteopenia in Long‐term Renal Transplant Patients with Alendronate. American Journal Of Transplantation 2002, 2: 62-67. PMID: 12095058, DOI: 10.1034/j.1600-6143.2002.020111.x.Peer-Reviewed Original ResearchConceptsBone mineral densityHigh bone turnoverRenal transplant patientsBone lossBone turnoverTransplant patientsTotal femurLumbar spineLong-term renal transplant patientsLong-term renal transplant recipientsBiochemical markersBiochemical parametersGood renal functionGroup A patientsRenal transplant recipientsBone turnover markersRegional bone mineral densityTreatment of osteoporosisSerum alkaline phosphataseFirst yearBisphosphonate therapyTransplant recipientsAlendronate therapyRenal functionA patients